0914 GMT - Sanofi's revised hospital drug-discount program in the U.S. holds long-term promise, although industry-wide implementation hurdles persist, Bryan Garnier Health analysts say in a note. The U.S. federal program, known as 340B and aimed at vulnerable patients, is increasingly used by hospitals to profit by charging the drugs' list prices while purchasing them at a discount, the analysts say. Under its new plan, Sanofi requires institutions to provide medical claims information before receiving discounts. Eli Lilly and Johnson & Johnson this month sued the federal government for rejecting similar rebate proposals. Sanofi reported in 2023 that discounts under Medicare and 340B led to a 15.7% decrease in its portfolio net price. Shares fall 0.3% to 92.89 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
November 25, 2024 04:15 ET (09:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.